Curcumin and cancer biology : Focusing regulatory effects in different signalling pathways

© 2021 John Wiley & Sons Ltd..

Cancer is the second-leading cause of death worldwide. Till date, many such effective treatments are available, for example chemotherapy, surgery, and radiation therapy, but there are severe associated side effects, such as increased infection risk, constipation, hair loss, anaemia, among others. Thus, the need for effective therapeutic strategies and screening methodology arises. Researchers around the world are increasingly trying to discover anticancer therapies with as few side effects as possible and many are now focusing on phytochemicals, like curcumin. Curcumin is a bright yellow substance isolated from the plant rhizomes of Curcuma longa L. To this molecule a high therapeutic benefit has been underlined, being able to alter the development of cancer by different mechanisms, such as regulating multiple microRNA expression, modifying a series of signalling pathways, that is, Akt, Bcl-2, PTEN, p53, Notch, and Erbb. Another major pathway that curcumin targets is the matrix metalloproteinase (MMP) gene expression. In fact, MMPs are responsible for the degradation of the cell-extracellular matrix, which can lead to the diseased condition and many different pathways contribute to its activity, such as JAK/STAT, NF-κB, MAPK/ERK, COX-2, ROS, TGF-β, among others. In this review, we have attempted to describe the curcumin regulatory effect on different cell signalling pathways involved in the progression of different types of cancers.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:35

Enthalten in:

Phytotherapy research : PTR - 35(2021), 9 vom: 21. Sept., Seite 4913-4929

Sprache:

Englisch

Beteiligte Personen:

Bhatia, Muskan [VerfasserIn]
Bhalerao, Mihir [VerfasserIn]
Cruz-Martins, Natália [VerfasserIn]
Kumar, Dileep [VerfasserIn]

Links:

Volltext

Themen:

Anticancer
Cell signalling pathways
Curcumin
IT942ZTH98
Journal Article
Matrix metalloproteins
NF-κB
Review

Anmerkungen:

Date Completed 29.09.2021

Date Revised 29.09.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1002/ptr.7121

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM323926541